Published in Neurology on May 23, 2006
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | NCT00904826
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol (2012) 2.45
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Clinical Reasoning: an unusual cause of transverse myelitis? Neurology (2014) 2.16
Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol (2012) 2.06
Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem (2011) 1.98
Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol (2009) 1.88
NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology (2010) 1.88
Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology (2014) 1.80
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology (2009) 1.78
AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology (2011) 1.77
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol (2012) 1.75
MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology (2015) 1.74
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
The complex genetics of multiple sclerosis: pitfalls and prospects. Brain (2008) 1.68
Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord (2012) 1.62
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol (2014) 1.60
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A (2011) 1.60
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci (2007) 1.59
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
Clinical approach to optic neuropathies. Clin Ophthalmol (2007) 1.52
Revised criteria for neuromyelitis optica--a new diagnostic standard? Nat Clin Pract Neurol (2007) 1.51
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm (2015) 1.49
Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. J Neurol (2013) 1.48
First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci (2014) 1.44
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Neuromyelitis optica: atipic clinic presentation. Neurol Sci (2011) 1.39
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology (2009) 1.38
Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology (2012) 1.34
Live cell analysis of aquaporin-4 m1/m23 interactions and regulated orthogonal array assembly in glial cells. J Biol Chem (2009) 1.34
Multiple sclerosis susceptibility alleles in African Americans. Genes Immun (2009) 1.32
Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation (2008) 1.32
Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol (2009) 1.31
An epidemiological study of neuromyelitis optica in Cuba. J Neurol (2009) 1.30
Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica. Nat Rev Neurol (2011) 1.30
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm (2014) 1.29
Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol (2015) 1.26
Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology (2012) 1.25
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One (2013) 1.21
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord (2011) 1.19
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm (2014) 1.17
Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol (2008) 1.17
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol (2012) 1.17
The adaptive immune system in diseases of the central nervous system. J Clin Invest (2012) 1.17
Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17
Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology (2007) 1.16
Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun (2012) 1.16
Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm (2015) 1.15
Demographic and clinical features of neuromyelitis optica: A review. Mult Scler (2015) 1.14
Familial neuromyelitis optica. Neurology (2010) 1.14
Two cases of benign neuromyelitis optica in patients with celiac disease. J Neurol (2009) 1.14
Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One (2011) 1.13
Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS One (2013) 1.13
Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol (2007) 1.12
HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology (2011) 1.11
Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol (2010) 1.11
Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J (2012) 1.10
Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol (2010) 1.10
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler (2012) 1.10
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol (2009) 1.10
Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol (2015) 1.10
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm (2015) 1.09
Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol (2012) 1.09
Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol (2012) 1.08
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia (2012) 1.08
Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08
Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol Sin (2011) 1.08
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry (2016) 1.08
Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol (2008) 1.08
Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol (2008) 1.07
Multiple sclerosis. N Engl J Med (2000) 12.69
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 4.93
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med (2000) 3.57
CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol (2001) 3.44
Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology (2009) 3.43
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain (2008) 3.05
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci (1976) 2.48
Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med (1975) 2.43
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
Immunoglobulins promote remyelination in the central nervous system. Ann Neurol (1990) 2.27
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med (1999) 2.12
CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10
Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology (1998) 2.08
Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology (1977) 1.78
Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS. Neurology (2008) 1.78
A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70
Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology (2011) 1.64
Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology (2003) 1.56
A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet (2000) 1.54
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med (1976) 1.53
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology (1999) 1.52
Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology (2004) 1.51
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med (1978) 1.51
Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology (1998) 1.46
A window of opportunity for no treatment in early multiple sclerosis? Mult Scler (2010) 1.45
ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol (2001) 1.45
Complete ophthalmoplegia as a complication of acute corticosteroid- and pancuronium-associated myopathy. Neurology (1991) 1.44
Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci (1976) 1.43
Seronegativity for type 1 antineuronal nuclear antibodies ('anti-Hu') in subacute sensory neuronopathy patients without cancer. Neurology (1993) 1.41
HTLV-1 associated myelopathy in Canada. Can J Neurol Sci (1989) 1.40
Immunologic properties of the main encephalitogenic peptide from the basic protein of human myelin. J Immunol (1970) 1.39
Neurological autoimmunity targeting aquaporin-4. Neuroscience (2009) 1.39
New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol (2000) 1.38
Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature (1980) 1.38
Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol (2001) 1.36
The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies. Neurology (1994) 1.36
Transitory expression of Thy-1 antigen in skeletal muscle development. Nature (1977) 1.32
Thy-1: a differentiation marker of potential mammary myoepithelial cells in vitro. Proc Natl Acad Sci U S A (1978) 1.31
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry (2010) 1.30
Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology (2004) 1.30
The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci (1976) 1.30
Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve (1982) 1.28
A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology (2005) 1.26
Multiple sclerosis: current pathophysiological concepts. Lab Invest (2001) 1.24
Retinocochleocerebral vasculopathy. Medicine (Baltimore) (1998) 1.23
Immunopharmacological disease: a break in tolerance to receptor sites. Lancet (1971) 1.23
Acquired Chiari I malformation secondary to spontaneous spinal cerebrospinal fluid leakage and chronic intracranial hypotension syndrome in seven cases. J Neurosurg (1998) 1.21
Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity. FASEB J (2001) 1.21
End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci (1976) 1.21
Paraneoplastic cerebellar degeneration: a clinical comparison of patients with and without Purkinje cell cytoplasmic antibodies. Mayo Clin Proc (1990) 1.19
Beta subunit heterogeneity in N-type Ca2+ channels. J Biol Chem (1996) 1.19
Brain-derived fibroblast growth factor: identity with a fragment of the basic protein of myelin. Proc Natl Acad Sci U S A (1978) 1.18
Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. J Exp Med (1986) 1.17
Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2011) 1.16
A case of multiple sclerosis presenting with inflammatory cortical demyelination. Neurology (2011) 1.16
Familial neuromyelitis optica. Neurology (2010) 1.14
The epidemiology of multiple sclerosis. Mayo Clin Proc (1997) 1.12
Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. J Autoimmun (1999) 1.11
Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology (2011) 1.11